SpecialtiesQuestion

Would you give adjuvant sunvozertinib to patients with stage II-III NSCLC with an EGFR exon 20 insertion mutation?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Is DLL3 expression necessary for tarlatamab efficacy in small cell lung cancer?

What high-risk features for stage I NSCLC would lead you to consider adjuvant osimertinib?

Which patients are you utilizing subcutaneous PD-1/L1 inhibitors instead of the intravenous formulation?

Would you recommend adjuvant immunotherapy after platinum-based chemotherapy for patients with in resected NSCLC with HER2 mutations?

How do you choose between Ipilimumab/Nivolumab (Checkmate 9LA) vs Durvalumab/Tremelimumab (POSEIDON) with chemotherapy in first line for mNSCLC with high PDL1, KEAP, and/or STK11 mutations?

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.